Calgary, Alberta – TheNewswire - September 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that the Company successfully completed its second surgical day in Mexico City as part of its ongoing clinical study evaluating the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).

All procedures were completed safely and without any reported issues or complications. These results further strengthen confidence in both the safety profile of the Ocumetics Lens and the surgical protocol designed to evaluate its performance. Group 1 patient surgeries are now completed.

Dean Burns, President and CEO of Ocumetics, commented “We are thrilled with the success of our second surgical day. The momentum we are building in this program gives us great excitement as we move forward in our clinical journey.”

The Company has not yet received all data from the one-month postoperative examinations of Group 1, Day 1 patients. An update will be provided when the one-month post operative results become available. 

The Company’s first-in-human clinical protocol was strategically designed to address three patient groups. The endpoints for each group are focused on the following key areas of evaluation:

 

Primary endpoints:

• Safety - establishing a clear baseline of patient health and recovery

• Distance vision correction - assessing the Ocumetics Lens’s ability to restore far vision

 

Secondary endpoints:

• Product handling and surgical delivery - ensuring procedural efficiency and reliability

• Near reading ability - evaluating the Ocumetics Len’s ability to restore close-range vision

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients.  Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.  

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Dave Burwell

Director, Investor Relations        

dave.burwell@ocumetics.com

 (403) 410-7907       

                       

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.